Valuation — not yet established
No valuation for DermBiont is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($86.6M) and the funding record below are the closest available signals.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
See the evidence behind this price
- ·Post-money valuations for all 7 rounds
- ·Watchlist + deal alerts for DermBiont
Create free account
No card required
Funding history
7 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Oct 2023 | Later Stage VC (Series B) | $35.2M | ▮ | ▮ |
| Mar 2023 | Debt | $4.7M | ▮ | ▮ |
| Sep 2022 | Debt | $2.5M | ▮ | ▮ |
| Dec 2021 | Early Stage VC (Series A2) | $35.4M | ▮ | ▮ |
| Oct 2020 | Early Stage VC (Series A2) | $7.2M | ▮ | ▮ |
| Feb 2020 | Debt | $2.9M | ▮ | ▮ |
| + 1 earlier rounds · a free account shows the full history | ||||
How DermBiont's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For DermBiont, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked
- How much has DermBiont raised?
- DermBiont has raised $86.6M in total funding across 7 recorded rounds.
- When did DermBiont last raise?
- DermBiont last raised in Oct 2023 (Later Stage VC (Series B)), raising $35.2M.